·Confidence 90%
CRISPR Therapeutics Underperforms in 2026 Market
Key takeaways
- CRISPR Therapeutics has seen only an 8% increase this year, lagging behind the Nasdaq Biotechnology Index and the S&P 500, raising concerns for investors.
Analysis
CRISPR Therapeutics has seen only an 8% increase this year, lagging behind the Nasdaq Biotechnology Index and the S&P 500, raising concerns for investors.
0 likes · 0 dislikes